Composition and method for treatment of depression and psychosis in humans
First Claim
Patent Images
1. A method for reducing at least one anxiogenic side effect of a selective 5-HT2A antagonist, the method comprising:
- administering to the subject an anxiogenic side effect-inducing amount ofa selective 5-HT2A antagonist selected from the group consisting of volinanserin (MDL-100907), eplivanserin (SR-46,349), pimavanserin, and pruvanserin (EMD-281,014);
once akathisia is induced, continuing to administer the selective 5-HT2A antagonist at a same dosage and frequency that caused the anxiogenic side effect; and
administering a therapeutically effective amount of a second composition comprising D-cycloserine (DCS) at a dosage in excess of 500 mg/day, wherein the DCS produces a NMDA receptor antagonistic blood plasma concentration measured at greater than 25 micrograms/mL, thereby reducing the anxiogenic side effect.
1 Assignment
0 Petitions
Accused Products
Abstract
Compositions and methods for the treatment of depression and psychoses in humans are disclosed. More particularly, the invention is directed to formulations containing antipsychotic and/or antidepressant medications and also containing an NMDAR antagonist. The present Invention Is also directed to methods tor the treatment of humans suffering from depression and other psychoses, including, schizophrenia, by administration of the inventive compositions in antidepressant and/or antipsychotic effective amounts.
-
Citations
16 Claims
-
1. A method for reducing at least one anxiogenic side effect of a selective 5-HT2A antagonist, the method comprising:
-
administering to the subject an anxiogenic side effect-inducing amount of a selective 5-HT2A antagonist selected from the group consisting of volinanserin (MDL-100907), eplivanserin (SR-46,349), pimavanserin, and pruvanserin (EMD-281,014); once akathisia is induced, continuing to administer the selective 5-HT2A antagonist at a same dosage and frequency that caused the anxiogenic side effect; and administering a therapeutically effective amount of a second composition comprising D-cycloserine (DCS) at a dosage in excess of 500 mg/day, wherein the DCS produces a NMDA receptor antagonistic blood plasma concentration measured at greater than 25 micrograms/mL, thereby reducing the anxiogenic side effect. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8)
-
-
9. A method for administering a selective 5-HT2A receptor antagonist to a subject, but with reduced anxiogenic side effects, the method comprising:
administering to a subject in need thereof an effective, side-effect-inducing amount of a selective 5-HT2A receptor antagonist selected from the group consisting of volinanserin (MDL-100907), eplivanserin (SR-46,349), pimavanserin, and pruvanserin (EMD-281,014); and a therapeutically effective amount of D-cycloserine (DCS) at a dosage in excess of 500 mg/day, wherein the administration of DCS produces a NMDA receptor antagonistic blood plasma concentration measured at greater than 25 micrograms/mL. - View Dependent Claims (10, 11, 12, 13, 14, 15, 16)
Specification